Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
The Artificial Pancreas Device System is a system of devices that closely mimics the glucose regulating function of a healthy pancreas.
Most Artificial Pancreas Device Systems consists of three types of devices already familiar to many people with diabetes: a continuous glucose monitoring system (CGM) and an insulin infusion pump. A blood glucose device (such as a glucose meter) is used to calibrate the CGM.
A computer-controlled algorithm connects the CGM and insulin infusion pump to allow continuous communication between the two devices. Sometimes an artificial pancreas device system is referred to as a "closed-loop" system, an "automated insulin delivery" system, or an "autonomous system for glycemic control."
An Artificial Pancreas Device System will not only monitors glucose levels in the body but also automatically adjusts the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia) with little or no input from the patient.
The classification of artificial pancreas devices systems includes threshold suspended device systems and hybrid closed-loop APDS, and the proportion of artificial pancreas devices systems in 2017 is about 60%, and the proportion is in decreasing trend from 2013 to 2017.
Artificial pancreas devices systems are widely used in hospital and clinic. The most proportion of artificial pancreas devices systems is in hospital, and the proportion in 2017 is about 59%.
North America is the largest consumption place, with a consumption market share nearly 54% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 35%.
Market competition is intense. Medtronic is the leader of the industry, and it holds key technologies and patents, with high-end customers; has been formed in the monopoly position in the industry.
Market Analysis and Insights: Global Artificial Pancreas Device System (APDS) Market
The research report studies the Artificial Pancreas Device System (APDS) market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Artificial Pancreas Device System (APDS) market size is projected to reach US$ 160.2 million by 2026, from US$ 81 million in 2020, at a CAGR of 12.1% during 2021-2026.
Global Artificial Pancreas Device System (APDS) Scope and Segment
The global Artificial Pancreas Device System (APDS) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Artificial Pancreas Device System (APDS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
Segment by Type, the Artificial Pancreas Device System (APDS) market is segmented into
Threshold Suspended DeviceSystems
Hybrid Closed-looPAPDS
Other Systems
Segment by Application, the Artificial Pancreas Device System (APDS) market is segmented into
Hospitals
Clinics
Global Artificial Pancreas Device System (APDS) market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The major vendors covered:
Medtronic
Bigfoot Biomedical
Beta Bionics
Admetsys
Insulet
Tandem Diabetes Care
Defymed
Most Artificial Pancreas Device Systems consists of three types of devices already familiar to many people with diabetes: a continuous glucose monitoring system (CGM) and an insulin infusion pump. A blood glucose device (such as a glucose meter) is used to calibrate the CGM.
A computer-controlled algorithm connects the CGM and insulin infusion pump to allow continuous communication between the two devices. Sometimes an artificial pancreas device system is referred to as a "closed-loop" system, an "automated insulin delivery" system, or an "autonomous system for glycemic control."
An Artificial Pancreas Device System will not only monitors glucose levels in the body but also automatically adjusts the delivery of insulin to reduce high blood glucose levels (hyperglycemia) and minimize the incidence of low blood glucose (hypoglycemia) with little or no input from the patient.
The classification of artificial pancreas devices systems includes threshold suspended device systems and hybrid closed-loop APDS, and the proportion of artificial pancreas devices systems in 2017 is about 60%, and the proportion is in decreasing trend from 2013 to 2017.
Artificial pancreas devices systems are widely used in hospital and clinic. The most proportion of artificial pancreas devices systems is in hospital, and the proportion in 2017 is about 59%.
North America is the largest consumption place, with a consumption market share nearly 54% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 35%.
Market competition is intense. Medtronic is the leader of the industry, and it holds key technologies and patents, with high-end customers; has been formed in the monopoly position in the industry.
Market Analysis and Insights: Global Artificial Pancreas Device System (APDS) Market
The research report studies the Artificial Pancreas Device System (APDS) market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Artificial Pancreas Device System (APDS) market size is projected to reach US$ 160.2 million by 2026, from US$ 81 million in 2020, at a CAGR of 12.1% during 2021-2026.
Global Artificial Pancreas Device System (APDS) Scope and Segment
The global Artificial Pancreas Device System (APDS) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Artificial Pancreas Device System (APDS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
Segment by Type, the Artificial Pancreas Device System (APDS) market is segmented into
Threshold Suspended DeviceSystems
Hybrid Closed-looPAPDS
Other Systems
Segment by Application, the Artificial Pancreas Device System (APDS) market is segmented into
Hospitals
Clinics
Global Artificial Pancreas Device System (APDS) market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The major vendors covered:
Medtronic
Bigfoot Biomedical
Beta Bionics
Admetsys
Insulet
Tandem Diabetes Care
Defymed
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
